View Item 

Show simple item record

Arterial Plasma Vasopressin and Aldosterone Predict Left Ventricular Mass in Men Who Develop Hypertension Over 20 Years
dc.contributor.authorStrand, Arne H.en_US
dc.contributor.authorGudmundsdottir, Helgaen_US
dc.contributor.authorFossum, Eigilen_US
dc.contributor.authorOs, Ingriden_US
dc.contributor.authorBjørnerheim, Reidaren_US
dc.contributor.authorKjeldsen, Sverre E.en_US
dc.date.accessioned2010-06-01T21:09:27Z
dc.date.available2010-06-01T21:09:27Z
dc.date.issued2007-05en_US
dc.identifier.citationStrand, Arne H . ; Gudmundsdottir, Helga; Fossum, Eigil; Os, Ingrid; BjØrnerheim, Reidar; Kjeldsen, Sverre E . (2007). "Arterial Plasma Vasopressin and Aldosterone Predict Left Ventricular Mass in Men Who Develop Hypertension Over 20 Years." The Journal of Clinical Hypertension 9(5): 365-371. <http://hdl.handle.net/2027.42/74239>en_US
dc.identifier.issn1524-6175en_US
dc.identifier.issn1751-7176en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74239
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17485972&dopt=citationen_US
dc.format.extent404421 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherLe Jacqen_US
dc.publisherBlackwell Publishing Ltden_US
dc.rights2007 Le Jacqen_US
dc.titleArterial Plasma Vasopressin and Aldosterone Predict Left Ventricular Mass in Men Who Develop Hypertension Over 20 Yearsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUllevaal University Hospital, Oslo, Norway, and the Department of Cardiovascular Medicine, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherDepartments of Cardiologyen_US
dc.contributor.affiliationotherNephrology,en_US
dc.identifier.pmid17485972en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74239/1/j.1524-6175.2007.06479.x.pdf
dc.identifier.doi10.1111/j.1524-6175.2007.06479.xen_US
dc.identifier.sourceThe Journal of Clinical Hypertensionen_US
dc.identifier.citedreferenceGlasser SP. Hypertension, hypertrophy, hormones, and the heart. Am Heart J. 1998; 135: S16 – S20.en_US
dc.identifier.citedreferenceCasale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986; 105: 173 – 178.en_US
dc.identifier.citedreferenceLevy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322: 1561 – 1566.en_US
dc.identifier.citedreferenceHaider AW, Larson MG, Benjamin EJ, et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998; 32: 1454 – 1459.en_US
dc.identifier.citedreferenceSchmieder RE. The role of non-haemodynamic factors of the genesis of LVH. Nephrol Dial Transplant. 2005; 20: 2610 – 2612.en_US
dc.identifier.citedreferenceKelm M, Schafer S, Mingers S, et al. Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens. 1996; 14: 1357 – 1364.en_US
dc.identifier.citedreferenceRostrup M, Smith G, Bjornstad H, et al. Left ventricular mass and cardiovascular reactivity in young men. Hypertension. 1994; 23: I168 – I171.en_US
dc.identifier.citedreferenceStrand AH, Gudmundsdottir H, Os I, et al. Arterial plasma noradrenaline predicts left ventricular mass independently of blood pressure and body build in men who develop hypertension over 20 years. J Hypertens. 2006; 24: 905 – 913.en_US
dc.identifier.citedreferenceChatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol. 2005; 95: 8B – 13B.en_US
dc.identifier.citedreferenceKjeldsen SE, Mundal R, Sandvik L, et al. Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men. J Hypertens. 2001; 19: 1343 – 1348.en_US
dc.identifier.citedreferenceOs I, Kjeldsen SE, Westheim A, et al. Decreased central dopaminergic activity in essential hypertension. J Hypertens. 1987; 5: 191 – 197.en_US
dc.identifier.citedreferenceOs I, Kjeldsen SE, Westheim A, et al. Endocrine and haemodynamic responses to graded dopamine infusion in essential hypertension. Scand J Clin Lab Invest. 1987; 47: 371 – 377.en_US
dc.identifier.citedreferenceOs I, Kjeldsen SE, Aakesson I, et al. Evidence of age-related variation in plasma vasopressin of normotensive men. Scand J Clin Lab Invest. 1985; 45: 263 – 268.en_US
dc.identifier.citedreferenceOmvik P, Enger E, Eide I. Effect of sodium depletion on plasma renin concentration before and during adrenergic beta-receptor blockade with propranolol in normotensive man. Am J Med. 1976; 61: 608 – 614.en_US
dc.identifier.citedreferenceDevereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57: 450 – 458.en_US
dc.identifier.citedreferenceSahn DJ, DeMaria A, Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978; 58: 1072 – 1083.en_US
dc.identifier.citedreferenceWachtell K, Smith G, Gerdts E, et al. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint. Am J Cardiol. 2000; 85: 466 – 472.en_US
dc.identifier.citedreferenceStruthers AD. Aldosterone: cardiovascular assault. Am Heart J. 2002; 144: S2 – S7.en_US
dc.identifier.citedreferenceSchlaich MP, Kaye DM, Lambert E, et al. Angiotensin II and norepinephrine release: interaction and effects on the heart. J Hypertens. 2005; 23: 1077 – 1082.en_US
dc.identifier.citedreferenceGrassi G, Vailati S, Bertinieri G, et al. Heart rate as marker of sympathetic activity. J Hypertens. 1998; 16: 1635 – 1639.en_US
dc.identifier.citedreferenceLee CR, Watkins ML, Patterson JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003; 146: 9 – 18.en_US
dc.identifier.citedreferenceYang XD, Zhao LY, Zheng QS, et al. Effects of arginine vasopressin on growth of rat cardiac fibroblasts: role of V1 receptor. J Cardiovasc Pharmacol. 2003; 42: 132 – 135.en_US
dc.identifier.citedreferenceBrilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993; 25: 563 – 575.en_US
dc.identifier.citedreferenceEpstein M. Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med. 2001; 94: 378 – 383.en_US
dc.identifier.citedreferenceKjeldsen SE, Eide I, Aakesson I, et al. Increased arterial catecholamine concentrations in 50-year-old men with essential hypertension. Scand J Clin Lab Invest. 1983; 43: 343 – 349.en_US
dc.identifier.citedreferenceOs I, Kjeldsen SE, Skjoto J, et al. Increased plasma vasopressin in low renin essential hypertension. Hypertension. 1986; 8: 506 – 513.en_US
dc.identifier.citedreferenceMoore TD, Nawarskas JJ, Anderson JR. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Heart Dis. 2003; 5: 354 – 363.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1524-6175.2007.06479.x.pdf
Size:
394.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.